2-15-05

Approved for use through 07/31/2006. OMB 0651-0031

PTO/SB/21 (08-03) U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number TRADE Application Number 10/049,366 TRANSMITTAL Filing Date February 1, 2002 **FORM First Named Inventor** Mie Takahashi (to be used for all correspondence after initial filing) 1641 Group Art Unit **Examiner Name** Leon Yun Bon Lum Total Number of Pages in This Submission Attorney Docket Number 967 026 ENCLOSURES (check all that apply) After Allowance Communication to Fee Transmittal Form Drawing(s) Technology Center (TC) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment / Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): Request for Refund Exhibits A-D and Return Mailroom Express Abandonment Request Postcard CD, Number of CD(s) Information Disclosure Statement Certified Copy of Priority The Commissioner is authorized to charge any additional fees Remarks Document(s) to Deposit Account No. 50-0289. Response to Missing Parts/ Incomplete Application Express Mail Label No. EV 303718978 US Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Wall Marjama & Bilinski LLP Firm Perer J. Bilinski Reg. No. 35,067 Individual name Signature Date February 14, 2005 **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service using the Express Mail Post Office To Addresset service per 37 CFR 1.10 under Express Mail No. EV 303718978 US addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 14, 2005. Typed or printed name Susanne C. Aregano Signature Date February 14, 2005 Mario Dane

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Practitioner's Docket No.: 967_026

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Mie Takahashi et al.

Serial No.:

10/049,366

Art Unit:

1641

Filed:

February 1, 2002

Examiner:

Leon Yun Bon Lum

Confirmation No.: 1103

For:

BIOSENSOR AND BLOOD COMPONENT ANALYTICAL METHOD

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 I hereby certify that this correspondence is being deposited with the United States Postal Service using the Express Mail Post Office To Addressee service per 37 CFR 1.10 under Express Mail No. EV 303718978 US addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 14, 2005.

Susanne C. Aregano

AMENDMENT

Sir:

In response to the Notice of Non-Compliant Amendment dated January 26, 2005, Applicants' herein resubmit the Response to the outstanding Office Action, dated August 23, 2004. To that end, Applicant's amend the above-identified patent application, without prejudice, as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.